m+Medelevator.RU
← Поиск публикаций
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lanskey Juliette H, Jafarian Amirhossein, Karadag Melek, Kocagoncu Ece, Williams Rebecca S, Yadav Pranay, Quinn Andrew J, Pitt Jemma, Thayanandan Tony, Lowe Stephen, Perkinton Michael, Timmers Maarten, Raymont Vanessa, Singh Krish D, Woolrich Mark, Nobre Anna C, Henson Richard N, Rowe James B

Аннотация

INTRODUCTION: Alzheimer's disease (AD) affects neurophysiology by loss of neurons, synapses, and neurotransmitters. A mechanistic understanding of the human disease will facilitate new treatments.

METHODS: Magnetoencephalography was recorded during an auditory mismatch negativity paradigm from healthy adults (n = 14) and people with symptomatic AD (n = 45, amyloid biomarker positive) at baseline and after 16 months. Fourteen people with AD had repeat magnetoencephalography at 2 weeks to assess test-retest reliability. Dynamic causal models were fitted to the evoked responses and analyzed using parametric empirical Bayes.

RESULTS: Sensor data confirmed that AD and its progression reduce the mismatch negativity amplitude, which had excellent test-retest reliability. Parametric empirical Bayes analyses confirmed that AD progressively reduces extrinsic connectivity between pyramidal cells and superficial pyramidal cell gain modulation.

DISCUSSION: Dynamic causal modeling revealed cellular-level causes of the neurophysiological deficits observed in AD. This approach may help facilitate experimental medicine studies of candidate treatments.

HIGHLIGHTS: Magnetoencephalography scanning provides reliable biomarkers that are sensitive to Alzheimer's disease (AD) and its progression, and informative about disease mechanisms underlying cognitive decline. In vivo assays of pyramidal cell function during cognitive processes in humans improve our understanding of AD mechanisms. The amplitude of the mismatch negativity response is progressively reduced in AD. Reduced pyramidal cell gain and connectivity underlie this neurophysiological deficit. These measures are potential biomarkers for interventional studies.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты